NEUE Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of -5.44% compared to NeueHealth's net margin of 2.02%. NeueHealth's return on equity of -3241.93% beat The Cigna Group's return on equity of 12.17%.

NeueHealth has a consensus price target of $7.00, signalling upside risk potential of 2.64%. On the other hand The Cigna Group has an analysts' consensus of $375.38 which suggests that it could grow by 23.86%. Given that The Cigna Group has higher upside potential than NeueHealth, analysts believe The Cigna Group is more attractive than NeueHealth.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cigna Group has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.43%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.92% to investors and pays a quarterly dividend of $1.51 per share. NeueHealth pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

NeueHealth quarterly revenues are $215.8M, which are smaller than The Cigna Group quarterly revenues of $65.5B. NeueHealth's net income of -$11.7M is lower than The Cigna Group's net income of $1.3B. Notably, NeueHealth's price-to-earnings ratio is -- while The Cigna Group's PE ratio is 16.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.06x versus 0.33x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

Clover Health Investments has a net margin of -5.44% compared to NeueHealth's net margin of -0.28%. NeueHealth's return on equity of -3241.93% beat Clover Health Investments's return on equity of -7.67%.

NeueHealth has a consensus price target of $7.00, signalling upside risk potential of 2.64%. On the other hand Clover Health Investments has an analysts' consensus of $4.69 which suggests that it could grow by 56.25%. Given that Clover Health Investments has higher upside potential than NeueHealth, analysts believe Clover Health Investments is more attractive than NeueHealth.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Clover Health Investments has a beta of 1.861, suggesting its more volatile than the S&P 500 by 86.075%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeueHealth pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

NeueHealth quarterly revenues are $215.8M, which are smaller than Clover Health Investments quarterly revenues of $462.3M. NeueHealth's net income of -$11.7M is lower than Clover Health Investments's net income of -$1.3M. Notably, NeueHealth's price-to-earnings ratio is -- while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.06x versus 1.00x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -5.44% compared to NeueHealth's net margin of 9.04%. NeueHealth's return on equity of -3241.93% beat Oscar Health's return on equity of 10.83%.

NeueHealth has a consensus price target of $7.00, signalling upside risk potential of 2.64%. On the other hand Oscar Health has an analysts' consensus of $15.81 which suggests that it could grow by 4.82%. Given that Oscar Health has higher upside potential than NeueHealth, analysts believe Oscar Health is more attractive than NeueHealth.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeueHealth pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

NeueHealth quarterly revenues are $215.8M, which are smaller than Oscar Health quarterly revenues of $3B. NeueHealth's net income of -$11.7M is lower than Oscar Health's net income of $275.3M. Notably, NeueHealth's price-to-earnings ratio is -- while Oscar Health's PE ratio is 53.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.06x versus 0.41x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -5.44% compared to NeueHealth's net margin of 4.65%. NeueHealth's return on equity of -3241.93% beat Progyny's return on equity of 11.16%.

NeueHealth has a consensus price target of $7.00, signalling upside risk potential of 2.64%. On the other hand Progyny has an analysts' consensus of $26.25 which suggests that it could grow by 11.85%. Given that Progyny has higher upside potential than NeueHealth, analysts believe Progyny is more attractive than NeueHealth.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.703%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeueHealth pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

NeueHealth quarterly revenues are $215.8M, which are smaller than Progyny quarterly revenues of $324M. NeueHealth's net income of -$11.7M is lower than Progyny's net income of $15.1M. Notably, NeueHealth's price-to-earnings ratio is -- while Progyny's PE ratio is 41.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.06x versus 1.82x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.